Leerink analyst Joseph Schwartz raised his price target for Sarepta to $55 from $50 after meeting with the company's management and gaining insight into their commercial-stage preparedness and other considerations following the FDA's accelerated approval of Exondys 51 in exon 51 skip-amenable Duchenne muscular dystrophy patients. The analyst believes the company is working hard to establish a robust pipeline of programs that could ultimately generate value. However, near-term he thinks the focus is primarily on the revenue ramp for Exondys 51. Schwartz reiterates a Market Perform rating on the shares as he believes it is prudent to wait for a better entry point.